News
News
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
16:00 - GlobeNewswire - Alternative Specialist, ITERAM Capital, Granted Asset Manager Licence
01/13/2021 / 10:00 - GlobeNewswire - DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy
01/12/2021 / 19:24 - GlobeNewswire - Family of Juan Garcia Files Claim Against Napa County, Sergeant David Ackman and Others for Unprovoked Killing of Garcia
01/12/2021 / 19:00 - GlobeNewswire - Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
01/08/2021 / 15:00 - GlobeNewswire - SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALXN, MGLN, FLIR, BEAT; Shareholders Are Encouraged to Contact the Firm
01/07/2021 / 19:55 - GlobeNewswire - Amarin Provides Preliminary 2020 Results and 2021 Outlook
01/07/2021 / 12:05 - GlobeNewswire - Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
01/06/2021 / 13:00 - GlobeNewswire - Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences
01/05/2021 / 14:30 - GlobeNewswire - BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
01/05/2021 / 13:00 - GlobeNewswire
Real-time